OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Advances in preclinical development can reduce development cost.
Single-use systems add complexity, reduce costs and timelines.
Characterization of virus-like particles enables process reproducibility and product consistency.
Technology advances and collaboration push more therapies closer to commercialization.
January 15, 2021
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.
January 14, 2021
The 17,000 m2 facility will serve as a process development and manufacturing site for Chinese companies developing medicines as well as multinationals with manufacturing requirements in China.
January 12, 2021
Under the terms of the agreement, operations will be initiated at Lonza’s Houston, TX Center of Excellence where Lonza will handle process development activities for late-clinical and commercial-scale GMP manufacturing of the cell therapy.
January 11, 2021
The draft guidance document offers developers of these treatments information regarding product development, preclinical testing, and clinical trial design.
January 06, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
Demand for specific advanced laboratory skills creates a positive employment market.
January 04, 2021
Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.
January 02, 2021
After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.
Essential bio/pharma employees show hard work and dedication can pay off, for patients.